Title
Compugen CPG-01-001 (Solid Tumors)
Study Title
A Phase 1a/1b study of COM701 as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors.
Malignancy
Ovarian, uterine, endometrial, breast, TNBC, lung, colon, CRC, NSCLC, head and neck, SCCHN, gastric, stomach, kidney, renal, RCC, bladder, transitional cell,
Investigational Agent
COM-701, PD(L)-1 antibody
Drug Class
PVRIG monoclonal antibody, PD(L)-1 antibody
Key Eligibility Criteria Details
- Histologically or cytologically confirmed, metastatic solid malignancy
- Has exhausted all available standard therapy or not a candidate for standard therapy
- ECOG PS 0-1
- Prior PD-1/PD-L1 allowed
- No other malignancy within 2 years prior
- No active autoimmune disease requiring systemic therapy within last 2 years
- No chronic steroids or immunosuppressants.
Objective
Primary- MTD, PK profile
Secondary- Immunogenicity, preliminary antitumor activity